May 9 Botox-maker Allergan Plc reported
a 5.1 percent rise in quarterly revenue on Tuesday, as sales of
its newer medicines helped offset declines in its older drugs.
Net loss attributable to ordinary shareholders was $2.63
billion, or $7.86 per share, in the first quarter, compared with
a profit of $186.1 million, or 47 cents per share, a year
The company reported a first-quarter loss primarily due to
amortization, research and development related charges and
in-process research and development impairments.
Net revenue for the acquisitive Dublin-based company, which
in February agreed to pay $2.48 billion for Zeltiq Aesthetics
Inc, rose to $3.57 billion from $3.40 billion.
(Reporting by Natalie Grover in Bengaluru; Editing by Martina